GLP-1 Drugs (Ozempic, Wegovy): Weight Loss & Bone Health Risks Revealed
The medical landscape is being reshaped by a new class of drugs – GLP-1 receptor agonists like Ozempic and Wegovy – transforming the management of type 2 diabetes and obesity. But as scientific understanding expands with five to ten years of follow-up data, emerging signals suggest a potential downside. A major study presented at the … Read more